BioSpace News Archive

LEQEMBI™ has the potential to make a difference for people living with early Alzheimer’s disease, their loved ones and healthcare professionals, and was recently approved by the U.S. Food and Drug Administration for the treatment of AD.

Based on hhc concept, our corporate philosophy, Eisai is committed to improve patients health outcomes and quality of life, simplify care delivery, increase health system efficiency and spur future investments in Alzheimer’s disease.

Nabriva Therapeutics plc (NASDAQ: NBRV) today announced that, after an assessment of strategic options, its Board of Directors approved a plan to preserve cash in order to adequately fund an orderly wind down of the Company’s operations.

atai Life Sciences announced that, while PCN-101 (R-ketamine) demonstrated signals of efficacy across all timepoints out to two weeks, Perception Neuroscience’s Phase 2a clinical trial did not meet its primary endpoint of a statistically significant change from baseline in participants’ MADRS (Montgomery-Åsberg Depression.

CASI Pharmaceuticals, Inc. announces that the China National Medical Products Administration (NMPA) has approved the Company’s Clinical Trial Application (CTA) for CB-5339, a first-in-class VCP/p97 inhibitor from Cleave Therapeutics.

Aeglea BioTherapeutics today announced an update to its corporate structure.

Baxter International Inc. announced a comprehensive strategic roadmap to meaningfully enhance its operational effectiveness, drive toward improved long-term performance, accelerate innovation and create additional value for all stakeholders.

Precision BioSciences today announced that the U.S. Food and Drug Administration (FDA) provided supportive Type C feedback on the Company’s CMC processes and analytical methods for azercabtagene zapreleucel (azer-cel; PBCAR0191).

CureVac N.V. (Nasdaq:CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced positive preliminary data from ongoing Phase 1 clinical programs in COVID-19 and seasonal flu, assessing both modified and unmodified mRNA technology.

Alterity Therapeutics Limited today announced that its Board of Directors approved a ratio change of its American Depository Shares (ADSs) to Ordinary Shares (the “ADS Ratio”) from the current ADS Ratio of 1 ADS representing 60 Ordinary Shares to 1 ADS representing 600 Ordinary Shares (the “ADS Ratio Change”).